Back to Search
Start Over
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
- Source :
-
NPJ breast cancer [NPJ Breast Cancer] 2023 Sep 19; Vol. 9 (1), pp. 76. Date of Electronic Publication: 2023 Sep 19. - Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 2374-4677
- Volume :
- 9
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- NPJ breast cancer
- Accession number :
- 37726304
- Full Text :
- https://doi.org/10.1038/s41523-023-00581-8